Molecular Partners (MOLN) and Orano Med said Tuesday that the latest preclinical data on their MP0712 product candidate confirmed "high tumor uptake" while keeping low kidney exposure.
The companies co-developed MP0712 as a radio-designed ankyrin repeat protein therapeutic candidate that targets delta-like ligand 3, according to the statement.
Molecular Partners and Orano Med said the latest data showed strong uptake by the targeted tissue, with minimal impact on health tissues. Dose-range finding studies in mice also confirmed that the treatment was well tolerated at relevant dosage.
The companies said they plan to start first-in-human studies in 2025, with initial clinical data on MP0712 expected within the same year.
Molecular Partners shares were up over 10% premarket.
Price: 7.47, Change: +0.69, Percent Change: +10.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.